{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T14:09:20Z","timestamp":1692972560667},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,3,2]],"date-time":"2014-03-02T00:00:00Z","timestamp":1393718400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s12185-014-1560-8","type":"journal-article","created":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T07:14:44Z","timestamp":1393658084000},"page":"782-785","source":"Crossref","is-referenced-by-count":2,"title":["Tumor lysis syndrome in a chronic lymphocytic leukemia patient with pleural effusion after oral fludarabine and cyclophosphamide therapy"],"prefix":"10.1007","volume":"99","author":[{"given":"Hideyuki","family":"Nakazawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Nishina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Senoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,2]]},"reference":[{"issue":"12","key":"1560_CR1","first-page":"1662","volume":"91","author":"M Brugiatelli","year":"2006","unstructured":"Brugiatelli M, Bandini G, Barosi G, Lauria F, Liso V, Marchetti M, et al. Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for bone marrow transplantation. Haematologica. 2006;91(12):1662\u201373.","journal-title":"Haematologica"},{"issue":"4","key":"1560_CR2","first-page":"263","volume":"7","author":"BD Cheson","year":"2009","unstructured":"Cheson BD. Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2009;7(4):263\u201371.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"7","key":"1560_CR3","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1200\/JCO.1998.16.7.2313","volume":"16","author":"BD Cheson","year":"1998","unstructured":"Cheson BD, Frame JN, Vena D, Quashu N, Sorensen JM. Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol. 1998;16(7):2313\u201320.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1560_CR4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ajh.10283","volume":"72","author":"K Hussain","year":"2003","unstructured":"Hussain K, Mazza JJ, Clouse LH. Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature. Am J Hematol. 2003;72(3):212\u20135.","journal-title":"Am J Hematol"},{"issue":"10","key":"1560_CR5","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.2010.31.1811","volume":"29","author":"JA Woyach","year":"2011","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA, et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011;29(10):1349\u201355.","journal-title":"J Clin Oncol"},{"issue":"9747","key":"1560_CR6","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164\u201374.","journal-title":"Lancet"},{"issue":"9","key":"1560_CR7","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/leu.2011.109","volume":"25","author":"KA Blum","year":"2011","unstructured":"Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM, et al. Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. Leukemia. 2011;25(9):1444\u201351.","journal-title":"Leukemia"},{"issue":"15","key":"1560_CR8","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.2007.13.9709","volume":"26","author":"LA Andritsos","year":"2008","unstructured":"Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008;26(15):2519\u201325.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1560_CR9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<247::AID-AJH9>3.0.CO;2-T","volume":"62","author":"H Yang","year":"1999","unstructured":"Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia. Am J Hematol. 1999;62(4):247\u201350.","journal-title":"Am J Hematol"},{"issue":"2","key":"1560_CR10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","volume":"109","author":"JC Byrd","year":"2007","unstructured":"Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 2007;109(2):399\u2013404.","journal-title":"Blood"},{"key":"1560_CR11","unstructured":"M\u00fcller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H. Chronic lymphocytic leukaemia\/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency of Research on Cancer; 2008. p. 180\u20132."},{"issue":"12","key":"1560_CR12","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446\u201356.","journal-title":"Blood"},{"issue":"2","key":"1560_CR13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12185-013-1393-x","volume":"98","author":"Y Ogawa","year":"2013","unstructured":"Ogawa Y, Ogura M, Suzuki T, Ando K, Uchida T, Shirasugi Y, et al. A phase I\/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Int J Hematol. 2013;98(2):164\u201370.","journal-title":"Int J Hematol"},{"issue":"31","key":"1560_CR14","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1200\/JCO.2007.14.2141","volume":"25","author":"LA Moutouh-de Parseval","year":"2007","unstructured":"Moutouh-de Parseval LA, Weiss L, DeLap RJ, Knight RD, Zeldis JB. Tumor lysis syndrome\/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol. 2007;25(31):5047.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1560_CR15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3109\/02841869709001295","volume":"36","author":"A Mahadevan","year":"1997","unstructured":"Mahadevan A, Kanegaonkar R, Hoskin PJ. Third space sequestration increases toxicity of fludarabine\u2014a case report. Acta Oncol. 1997;36(4):441.","journal-title":"Acta Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1560-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-014-1560-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1560-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T02:41:02Z","timestamp":1565232062000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-014-1560-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,2]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["1560"],"URL":"https:\/\/doi.org\/10.1007\/s12185-014-1560-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,2]]}}}